medigraphic.com

2010, Number 3

<< Back Next >>

Rev Hematol Mex 2010; 11 (3)

Molecular markers of myeloproliferative syndromes

Navarro VM

Language: Spanish
References: 27
Page: 152-155
PDF size: 58.17 Kb.


ABSTRACT

Myeloproliferative neoplasms are a group of diseases characterized by the presence of genetic re-arrangements or somatic mutations in the genes coding for proteins or receptors that are related to the activity protein tyrosine kinase such as BCR / ABL, JAK 2 and RFCDP 1, conferring proliferative and survival advantage to myeloid neoclassical clone whatever type granulocytic, erythroid or megacatiocitco. Chronic myeloid leukemia is characterized by the coexistence of t (9; 22) or Philadelphia chromosome, which marker is sufficient to start the disease and which can be used for the investigation of minimal residual disease after therapy with white the resulting chimeric protein.


REFERENCES

  1. Dameshek W. Some speculations on the myeloproliferative síndromes. Blood 1951;6:372-375.

  2. Tefferi A and Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.

  3. Hehlmann R, Hochhaus A and Baccarani M. European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-350.

  4. Hasserjian R. Chronic Myelogenous Leukemia. Texas. Dan Jones Houston 2010 193-211.

  5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.

  6. Kralovics R, Passamonti F, Buser A, Teo S, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.

  7. Faderl S, Talpaz M, Estrov Z, O’Brien S, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.

  8. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.

  9. Goldman J, Melo J. Chronic Myeloid Leukemia. Advances in Biology and New Approaches to Treatment. N Engl J Med 2003;349:1451-1464.

  10. Vardiman J, Melo J, Baccarani M, Thiele J. Chronic myelogenous leukaemia, BCR-ABL 1 positive. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:32-37.

  11. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, et al. Survival advantage from imatinib compared with the combination interferon-plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484.

  12. Marcucci G, Perrotti D, Caligiuri M. Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance. Clin Cancer Res 2003;9:1333-1337.

  13. Hughes T, Deininger M, Hochhaus A, Branford S, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.

  14. Thiele J, Kvasnicka H, Orazi A, Tefferi A, Birgegard G. Polycythaemia vera Lyon. In: Swerdlow S, Campo E, Harris N, Jaffe E, et al. FALTAN DATOS 2008;pp:40-43.

  15. Tefferi A, Skoda R, Vardiman J. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009;6:627-637.

  16. Chen G, Prchal J. Polycythemia vera and its molecular basis: An update. Best Pract & Res Clin Haematol 2006;19:387-397.

  17. Streiff M, Smith B, Spivak J. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Blood 2002;99:1144-1149.

  18. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 2006;13:93-98.

  19. Thiele J, Kvasnicka H, Orazi A, Tefferi A, Gisslinger H. Essential thrombocythaemia. Lyon. In: Swerdlow S, Campo E, Harris N, et al. FALTA EL TÍTULO 2008;pp:48-50.

  20. Antonioli E, Guglielmelli P, Pancrazzi A, Verrucci M, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849.

  21. Thiele J, Kvasnicka H, Tefferi A, Barosi G, et al. Primary myelofibrosis. Lyon. In. Swerdlow S, Campo E, Harris N, Jaffe E, et al. FALTAN DATOS 2008;pp:44-47.

  22. Barosi G, Bergamaschi G, Marchetti M, et al. Splenomegaly and leukemic transformation in primary myelofibrosis JAK2 V617F mutational status predicts progression to large. Blood 2007;110:4030-4036.

  23. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.

  24. Bain B, Gilliland D, Vardiman J. and Horny H. Chronic eosinophilic leukaemia not otherwise specified. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:48-50.

  25. Tefferi A, Patnaik M and Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133:468-492.

  26. Horny H, Metcalfe D, Bennett J. and Bain B. Mastocytosis. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:57-63.

  27. Garcia-Montero A, Jara-Acevedo A, Teodosio C, Sanchez M, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Networkon Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372.




2020     |     www.medigraphic.com